May support evaluation Common Eligibility Factors BMI of 30 or greater BMI of 27 or greater with a related health condition Prior lifestyle efforts without durable results Ability to attend monitoring and report symptoms Willingness to support nutrition, movement, and maintenance Needs more review Reasons to Avoid, Delay, or Modify Treatment Pregnancy, planned pregnancy, or breastfeeding Personal or family history of medullary thyroid carcinoma or MEN2 for Wegovy/Zepbound Severe gastroparesis or significant gastrointestinal disease Active or unstable eating disorder Prior serious allergy to the medicine Inability to maintain fluid or nutrition Medication interactions or uncontrolled illness These medicines are not intended for cosmetic weight loss The goal is treatment of obesity or clinically significant overweight-related risknot rapid loss of a few pounds for an event
Intravenous dl-carnitine fails to increase the double-product during atrial pacing in patients with effort angina
During the study, body weight and food intake were measured every 23 days as indicated and body composition was measured pre-treatment and post-treatment as indicated by nuclear magnetic resonance (EchoMRI)
26,28 The specific issue related to randomization was this: Randomization was not conducted consistently and correctly across all sites
Canadas Health Canada had approved two generic versions of Ozempic and was reviewing submissions for seven further products by mid-2026